Mavyret’s more common side effects include headache, fatigue (lack of energy), and nausea. Other possible side effects can be mild or serious, and can include: diarrhea; itchiness; allergic reaction ...

Mavyret is approved to treat hepatitis C caused by genotypes 1 to 6 if you haven’t received treatment for hepatitis C and don’t have cirrhosis. For this use, the recommended Mavyret dose is ...

--AbbVie today announced that the U.S. Food and Drug Administration approved a label expansion for MAVYRET ®, an oral pangenotypic direct acting antiviral therapy. HCV is a highly infectious ...

Shares of AbbVie (ABBV) traded over 1% higher on Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) approved an expanded treatment scope for its drug Mavyret.

Mavyret Indication Expanded to Include Treatment of Acute Hepatitis C Virus: Yeztugo (lenacapavir) HIV-1 capsid inhibitor: For pre-exposure prophylaxis to reduce the risk of sexually acquired HIV ...

In 2019, the FDA approved Mavyret to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all ...

“Mavyret has treated more than one million patients with HCV, but we recognize that a significant need remains for patients with acute infection,” Roopal Thakkar, MD, executive vice president ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.

The label expansion was supported by data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of MAVYRET eight-week treatment in adults with acute HCV ...

NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for MAVYRET® (glecaprevir ...

FDA Expands Mavyret Use to Acute Hepatitis C: Mavyret is now the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C (HCV) in patients aged three years and ...